ANI PHARMACEUTICALS, INC (ANIP) Current Ratio
- Current ratio · latest quarter: Value 2.91×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.91× | Current assets / current liabilities. $825.43M ÷ $283.65M ≈ 2.91× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 825.43M USD | Assets, Current |
| Current obligations | 283.65M USD | Liabilities, Current |
| Cash and equivalents | 360.21M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 274.47M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 143.15M USD | Inventory, Net |
| Payables | 73.83M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 21.33M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $825.43M | $283.65M | $360.21M | (m) | $274.47M | $143.15M | $73.83M | $21.33M | 2.91× |
| 2026-03-31 | $747.08M | $239.51M | $311.18M | (m) | $255.43M | $143.47M | $69.69M | $19.30M | 3.12× |
| 2025-12-31 | $753.12M | $278.11M | $285.58M | (m) | $281.08M | $143.07M | $62.58M | $17.27M | 2.71× |
| 2025-09-30 | $698.40M | $270.56M | $262.61M | (m) | $252.62M | $146.47M | $69.80M | $15.24M | 2.58× |
| 2025-06-30 | $602.63M | $236.84M | $217.80M | (m) | $225.65M | $138.31M | $54.57M | $13.22M | 2.54× |
| 2025-03-31 | $536.29M | $201.81M | $149.80M | (m) | $220.33M | $137.41M | $53.06M | $11.19M | 2.66× |
| 2024-12-31 | $528.46M | $194.45M | $144.86M | (m) | $221.73M | $136.78M | $45.66M | $9.17M | 2.72× |
| 2024-09-30 | $521.30M | $189.93M | $144.98M | (m) | $196.36M | $148.04M | $60.89M | $7.15M | 2.74× |
| 2024-06-30 | $555.46M | $139.98M | $240.11M | (m) | $166.09M | $125.45M | $48.68M | $850.00K | 3.97× |
| 2024-03-31 | $540.56M | $136.89M | $228.60M | (m) | $172.42M | $113.84M | $49.43M | $850.00K | 3.95× |
| 2023-12-31 | $519.82M | $145.48M | $221.12M | (m) | $162.08M | $111.20M | $36.68M | $850.00K | 3.57× |
| 2023-09-30 | $497.22M | $134.35M | $193.08M | (m) | $178.84M | $106.59M | $34.08M | $850.00K | 3.70× |
| 2023-06-30 | $459.31M | $122.86M | $161.71M | (m) | $172.93M | $104.32M | $28.50M | $850.00K | 3.74× |
| 2023-03-31 | $364.75M | $125.83M | $67.76M | (m) | $174.71M | $103.65M | $32.69M | $850.00K | 2.90× |
| 2022-12-31 | $344.26M | $99.44M | $48.23M | (m) | $165.44M | $105.36M | $29.30M | $850.00K | 3.46× |
| 2022-09-30 | $309.38M | $81.63M | $56.28M | (m) | $140.43M | $95.89M | $18.99M | $850.00K | 3.79× |
| 2022-06-30 | $322.40M | $96.31M | $63.38M | (m) | $150.41M | $92.55M | $27.64M | $850.00K | 3.35× |
| 2022-03-31 | $301.40M | $79.53M | $76.91M | (m) | $131.63M | $83.16M | $22.06M | $850.00K | 3.79× |
| 2021-12-31 | $321.77M | $87.54M | $100.30M | (m) | $128.53M | $81.69M | $22.97M | $850.00K | 3.68× |
| 2021-09-30 | $191.38M | $84.87M | $15.25M | (m) | $106.71M | $61.68M | $11.51M | $15.93M | 2.25× |
| 2021-06-30 | $191.80M | $89.45M | $24.26M | (m) | $92.65M | $67.63M | $12.98M | $15.18M | 2.14× |
| 2021-03-31 | $182.80M | $82.77M | $25.07M | (m) | $91.88M | $59.93M | $13.77M | $14.44M | 2.21× |
| 2020-12-31 | $170.32M | $78.56M | $7.86M | (m) | $95.79M | $60.80M | $11.26M | $13.24M | 2.17× |
| 2020-09-30 | $165.82M | $75.90M | $17.90M | (m) | $83.75M | $59.20M | $13.46M | $12.79M | 2.18× |
| 2020-06-30 | $156.54M | $79.09M | $27.70M | (m) | $73.16M | $52.56M | $14.21M | $12.33M | 1.98× |
| 2020-03-31 | $158.66M | $79.36M | $20.41M | (m) | $82.38M | $52.90M | $12.48M | $11.87M | 2.00× |
| 2019-12-31 | $187.69M | $61.68M | $62.33M | (m) | $72.13M | $48.16M | $14.61M | $9.94M | 3.04× |
| 2019-09-30 | $182.39M | $170.71M | $59.67M | (m) | $70.70M | $46.17M | $10.95M | $4.15M | 1.07× |
| 2019-06-30 | $168.91M | $166.79M | $40.59M | (m) | $76.27M | $45.30M | $9.81M | $4.15M | 1.01× |
| 2019-03-31 | $151.83M | $165.07M | $38.23M | (m) | $67.41M | $42.03M | $10.52M | $3.24M | 0.92× |
| 2018-12-31 | $152.88M | $165.55M | $43.01M | (m) | $64.84M | $40.50M | $8.88M | $3.26M | 0.92× |
| 2018-09-30 | $156.79M | $46.90M | $44.14M | (m) | $67.65M | $40.01M | $7.26M | $5.69M | 3.34× |
| 2018-06-30 | $152.37M | $39.68M | $54.99M | (m) | $56.12M | $37.76M | $7.95M | $5.22M | 3.84× |
| 2018-03-31 | $143.39M | $39.65M | $51.97M | (m) | $54.80M | $34.29M | $4.89M | $3.81M | 3.62× |
| 2017-12-31 | $131.60M | $39.23M | $31.14M | (m) | $58.79M | $37.73M | $3.63M | $3.35M | 3.35× |
| 2017-09-30 | $125.58M | $36.38M | $18.03M | (m) | $62.17M | $38.48M | $5.82M | (m) | 3.45× |
| 2017-06-30 | $112.86M | $28.29M | $8.37M | (m) | $55.51M | $42.31M | $3.15M | (m) | 3.99× |
| 2017-03-31 | $106.98M | $32.42M | $10.83M | (m) | $46.70M | $45.89M | $4.79M | (m) | 3.30× |
| 2016-12-31 | $103.01M | $31.95M | $27.36M | (m) | $45.90M | $26.18M | $3.39M | $0.00 | 3.22× |
| 2016-09-30 | $95.47M | $30.49M | $16.16M | (m) | $47.48M | $28.26M | $4.73M | (m) | 3.13× |
| 2016-06-30 | $79.82M | $24.73M | $15.01M | (m) | $35.56M | $25.05M | $4.96M | (m) | 3.23× |
| 2016-03-31 | $116.55M | $16.21M | $77.75M | (m) | $22.48M | $13.92M | $3.04M | (m) | 7.19× |
| 2015-12-31 | $192.58M | $11.76M | $154.68M | (m) | $21.93M | $13.39M | $2.07M | (m) | 16.38× |
| 2015-09-30 | $197.52M | $12.19M | $150.91M | (m) | $21.64M | $13.74M | $2.63M | (m) | 16.20× |
| 2015-06-30 | $208.95M | $6.95M | $166.73M | (m) | $18.88M | $12.70M | $1.32M | (m) | 30.07× |
| 2015-03-31 | $202.99M | $9.07M | $165.56M | (m) | $17.37M | $10.74M | $2.29M | (m) | 22.37× |
| 2014-12-31 | $194.99M | $13.23M | $169.04M | (m) | $17.30M | $7.52M | $2.65M | (m) | 14.74× |
| 2014-09-30 | $57.56M | $8.14M | $35.05M | (m) | $14.57M | $7.35M | $3.06M | (m) | 7.07× |
| 2014-06-30 | $67.16M | $3.83M | $52.96M | (m) | $7.79M | $5.91M | $1.73M | (m) | 17.54× |
| 2014-03-31 | $67.94M | $4.56M | $51.37M | (m) | $10.91M | $5.09M | $2.66M | (m) | 14.90× |
| 2013-12-31 | $27.72M | $3.54M | $11.11M | (m) | $12.51M | $3.52M | $1.43M | (m) | 7.83× |
| 2013-09-30 | $26.09M | $6.60M | $10.93M | (m) | $9.52M | $2.81M | $2.09M | (m) | 3.96× |
| 2013-06-30 | $24.12M | $6.16M | $12.59M | (m) | $6.43M | $2.58M | $1.63M | (m) | 3.91× |
| 2012-12-31 | $8.57M | $7.71M | $11.00K | (m) | $5.43M | $2.81M | $1.99M | (m) | 1.11× |
| 2012-09-30 | $38.58M | $10.92M | $38.05M | (m) | (m) | (m) | $2.00M | (m) | 3.53× |
| 2012-06-30 | $42.93M | $16.37M | $42.42M | (m) | (m) | (m) | $3.84M | (m) | 2.62× |
| 2012-03-31 | $50.19M | $6.08M | $49.47M | (m) | (m) | (m) | $3.28M | (m) | 8.25× |
| 2011-12-31 | $58.03M | $7.23M | $57.23M | (m) | (m) | (m) | $3.15M | (m) | 8.03× |
| 2011-09-30 | $70.54M | $11.50M | $69.60M | (m) | (m) | (m) | $6.04M | (m) | 6.13× |
| 2011-06-30 | $38.14M | $11.48M | $37.13M | (m) | (m) | (m) | $6.35M | (m) | 3.32× |
| 2010-12-31 | $40.63M | $8.18M | $38.16M | (m) | (m) | (m) | $4.86M | (m) | 4.96× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |